Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2003 March;55(1) > Minerva Urologica e Nefrologica 2003 March;55(1):43-56

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

REVIEWS  


Minerva Urologica e Nefrologica 2003 March;55(1):43-56

language: English

Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation

Ciancio G., Mattiazzi A., Miller J., Burke G. W.

Division of Transplantation, Department of Surgery, University of Miami School of Medicine, Miami, FL, USA


PDF  


Acute re­jec­tion ­still re­mains a ma­jor prob­lem in or­gan trans­plan­ta­tion and is a sig­nif­i­cant ­risk fac­tor for chron­ic re­jec­tion, and chron­ic re­jec­tion is one of the ­most im­por­tant caus­es of ­late ­graft ­loss. Current new im­mu­no­sup­pres­sive ­drugs ­such as ta­crol­i­mus, ra­pam­y­cin and my­co­phen­o­late mofe­til ­have ­been de­vel­oped to re­duce ­acute re­jec­tion and to im­prove re­nal al­lo­graft sur­vi­val. More re­cent­ly, anti­hu­man anti­bod­ies, ei­ther mono­clo­nal or poly­clo­nal, ­have ­been de­vel­oped to use for in­duc­tion ther­a­py at the ­time of trans­plan­ta­tion or to ­treat re­jec­tion. Daclizumab, a new en­gi­neered hu­man im­mu­no­glob­u­lin mono­clo­nal anti­body to the inter­leu­kin-2 re­cep­tor α-sub­unit was ap­proved to pre­vent ­acute re­jec­tion af­ter sol­id or­gan trans­plan­ta­tion. Data ­from clin­i­cal ­trials ­show da­cliz­u­mab to be ­well tol­er­at­ed in sol­id or­gan trans­plan­ta­tion. It ­does not in­crease the in­ci­dence of in­fec­tion, in­clud­ing cy­tom­e­gal­o­vi­rus in­fec­tion.

top of page

Publication History

Cite this article as

Corresponding author e-mail